Draig Therapeutics

Draig Therapeutics
Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.
About
Technology stack
detected 2026-07-14“Ion channel ligands in clinical development – Quarterly review (Q4 2025). The main focus of this series is to highlight the progress being made in ion channel clinical drug development, which is a key validation parameter for target selecti…”
View on Reddit“Cardiff (Wales) Based Biotech Draig Therapeutics Emerge From Stealth.”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.
What does Draig Therapeutics do?
Draig Therapeutics is developing transformative neuropsychiatric therapies designed to restore the brain to a healthier state. Their approach utilizes highly specific neuromodulators, with a lead program, DT-101, targeting major depressive disorder by potentiating AMPA receptors. The company is committed to co-creating with patients and care partners to develop best-in-class treatments for prevalent and underserved neuropsychiatric disorders.
How much funding has Draig Therapeutics raised?
Draig Therapeutics has raised a total of $65M in funding. The most recent round on record is Series B.
Where is Draig Therapeutics headquartered?
Draig Therapeutics is headquartered in Newton, Massachusetts, United States.
What industry does Draig Therapeutics operate in?
Draig Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Neuroscience, Biotech, Drug Discovery.
What is Draig Therapeutics's revenue?
StartupHub estimates Draig Therapeutics's annual revenue at $8.2M (range $2.1M to $27.3M, 37% confidence), based on comparable companies in the sector.
What is Draig Therapeutics's valuation?
StartupHub estimates Draig Therapeutics's effective valuation at $260.0M (range $162.5M to $390.0M, 25% confidence), based on comparable companies in the sector.